Ruei-Min Lu, Ph.D
Associate Research Scientist
Principal Investigator of Antibody R&D core facility in Biomedical Translation Center, Academia Sinica
Office: BioTReC B301 (National Biotechnology Research Park)
Office TEL: (02)7750-5844
Lab TEL: (02)7750-5800 #2301 #2313
E-mail: reminlu@gate.sinica.edu.tw
RESEARCH SUMMARY
My research primarily focuses on two fields, antibody engineering and cancer research, and includes components of both basic and translational research. Today, I have published 22 peer-reviewed papers and granted 13 patents. For example, we generated anti-c-Met and anti-VEGFR2 human antibodies from the phage display scFv library, which showed therapeutic effectiveness against cancers in vitro and in vivo studies. Both antibodies have been licensed to biotech companies to develop antibody drugs for cancer. A total of 12 antibody patents and 3 related technologies were licensed to biotech companies to further develop therapeutics and diagnostics for human diseases. During the global COVID-19 pandemic, we participated in the country's epidemic prevention mission to establish two critical products, namely the COVID-19 serological lateral flow rapid screening kit and the NP antigen rapid screening kit. Two products were received Emergency Use Authorization (EUA) from Taiwan FDA in 2020 and 2021, respectively. Apart from working in academia, I have served as a scientist in the biotech industry for two years, in which I was responsible for conducting pre-clinical studies of antibody drugs. Currently, I serve as a principle investigator to manage human therapeutic antibody core facility in Biomedical Translation Center, Academia Sinica. Here, we established the new generation of phage display human scFv library, human single B cell, and mouse hybridoma technology to provide antibody discovery services. Our clienteles covered academic units and biotech companies. Antibody affinity maturation, antibody humanization and epitope mapping also have been established. Highly specific and sensitive antibodies will efficiently accelerate academic research, as well as development of drug and diagnostic reagentdevelopment.
Lu, R.M et al. Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science 27, 1, 2020 ( >2,402 citations, Nov 07, 2025 updated) https://doi.org/10.1186/s12929-019-0592-z
EXPERIENCES
2025 – now Associate Research Scientist
Human Therapeutic Antibody R&D Platform in Biomedical Translation Center, Academia Sinica
2021 – 2025 Assistant Research Scientist
Human Therapeutic Antibody R&D Platform in Biomedical Translation Center, Academia Sinica
2019 – 2021 Senior Project Scientist and Group Leader
Human Therapeutic Antibody R&D Platform in Biomedical Translation Center, Academia Sinica
2015 – 2019 Senior Project Scientist
Institute of Cellular and Organismic Biology, Academia Sinica
2013 – 2015 Research Scientist
New drug development center, Biotech Co., Ltd., Taipei, Taiwan
2011 – 2013 Post-Doctoral scholar
Institute of Cellular and Organismic Biology, Academia Sinica
2002 – 2006 Research Assistant (Military Service)
Institute of Biomedical Science, Academia Sinica
EDUCATION
2006 – 2011 Ph.D. Graduate Institute of Life Sciences, National Defense Medical Center; ICOB, Academia Sinica, Taiwan
2000 – 2002 MS. Graduate Institute of Pathology, National Taiwan University, Taiwan
1996 – 2000 BS. Department of Medical Technology, Tzu-Chi Medical University, Taiwan
RESEARCH FIELD
1. Construction of phage-displayed human naïve scFv & Fab libraries
2. Discovery of novel human antibody
3. Antibody humanization
4. Antibody affinity maturation
5. Antibody engineering
6. Identification of antibody VH/VL sequences
7. Identification of antibody epitope
8. Antibody and peptides-mediated targeted drug delivery system
PUBLICATIONS
- Ruei-Min Lu, Hsiao-Ling Chiang, Joyce Pei-Yi Yuan, Hsiu-Hua Wang, Chi-Yung Chen, Sushree Shankar Panda, Kang-Hao Liang, Hung-Pin Peng, Shih-Han Ko, Hung-Ju Hsu, Monika Kumari, Yi-Jen Su, Yi-Ting Tse, Nai-Lin Chou, Han-Chung Wu. (2025) Technological advancements in antibody-based therapeutics for treatment of diseases. Journal of Biomedical Science. 32, 98. https://doi.org/10.1186/s12929-025-01190-2
- Ruei-Min Lu, Hsiang-En Hsu, Ser John Lynon P Perez, Monika Kumari, Guan-Hong Chen, Ming-Hsiang Hong, Yin-Shiou Lin, Ching-Hang Liu, Shih-Han Ko, Christian Angelo P Concio, Yi-Jen Su, Yi-Han Chang, Wen-Shan Li, Han-Chung Wu. (2024) Current landscape of mRNA technologies and delivery systems for new modality therapeutics. Journal of Biomedical Science. 31, 89. https://doi.org/10.1186/s12929-024-01080-z
- Hsiao-Ling Chiang, Kang-Hao Liang, Ruei-Min Lu, Ting-Wen Kuo, Yi‑Ling Lin, Han-Chung Wu. (2023) Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2. Journal of Biomedical Science. 30, 59. https://doi.org/10.1186/s12929-023-00955-x
- Ruei-Min Lu, Kang-Hao Liang, Hsiao-Ling Chiang, Fu-Fei Hsu, Hsiu-Ting Lin, Wan-Yu Chen, Feng-Yi Ke, Monika Kumari, Yu-Chi Chou, Mi-Hua Tao, Yi-Ling Lin, Han-Chung Wu. (2023) Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon. 9, e15587 https://doi.org/10.1016/j.heliyon.2023.e15587.
- Monika Kumari*, Ruei-Min Lu*, Mu-Chun Li, Jhih-Liang Huang, Fu-Fei Hsu, Shih-Han Ko, Feng-Yi Ke, Shih-Chieh Su, Kang-Hao Liang, Joyce Pei-Yi Yuan, Hsiao-Ling Chiang, Cheng-Pu Sun, I.-Jung Lee, Wen-Shan Li, Hsing-Pang Hsieh, Mi-Hua Tao & Han-Chung Wu. (2022) A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Journal of Biomedical Science. 29, 68. https://doi.org/10.1186/s12929-022-00852-9 (*Co-First Author)
- Yu-Chyi Hwang*, Ruei-Min Lu*, Shih-Chieh Su, Pao-Yin Chiang, Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, Tzung-Yang Hsieh & Han-Chung Wu. (2022) Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Journal of Biomedical Science. 29, 1. https://doi.org/10.1186/s12929-021-00784-w (*Co-First Author)
- Ruei-Min Lu, Shih-Han Ko, Wan-Yu Chen, Yu-Ling Chang, Hsiu-Ting Lin and Han-Chung Wu. (2021) Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19. International Journal of Molecular Science. 22, 12412. https://doi.org/10.3390/ijms222212412
- Kang-Hao Liang; Pao-Yin Chiang; Shih-Han Ko; Yu-Chi Chou; Ruei-Min Lu; Hsiu-Ting Lin; Wan-Yu Chen; Yi-Ling Lin; Mi-Hua Tao; Jia-Tsrong Jan; Han-Chung Wu. (2021) Antibody cocktail effective against variants of SARS-CoV-2. Journal of Biomedical Science. 28, 80 https://doi.org/10.1186/s12929-021-00777-9 PMID: 34814920
- Su, S.-C.; Yang, T.-J.; Yu, P.-Y.; Liang, K.-H.; Chen, W.-Y.; Yang, C.-W.; Lin, H.-T.; Wang, M.-J.; Lu, R.-M.; Tso, H.-C.; Chung, M.-J.; Hsieh, T.-Y.; Chang, Y.-L.; Lin, S.-C.; Hsu, F.-Y.; Ke, F.-Y.; Wu, Y.-H.; Hwang, Y.-C.; Liu, I. J.; Liang, J.-J.; Liao, C.-C.; Ko, H.-Y.; Sun, C.-P.; Wu, P.-Y.; Jan, J.-T.; Chang, Y.-C.; Lin, Y.-L.; Tao, M.-H.; Hsu, S.-T. D.; Wu, H.-C. (2021) Structure-guided antibody cocktail for prevention and treatment of COVID-19. PLOS Pathogens 17, (10), e1009704. https://doi.org/10.1371/journal.ppat.1009704 PMID: 34673836
- Ruei-Min Lu., Wu CH, Patil A.V., Wu, H.C. (2020) Chapter 23: Peptide Targeting Methods. Handbook of In Vivo Chemistry in Mice: From Lab to Living System. WILEY-VCH Book, ISBN 9783527344321. (Invited review article) https://doi.org/10.1002/9783527344406.ch16
- Ruei-Min Lu, Yu-Chyi Hwang, I-Ju Liu, Chi-Chiu Lee, Han-Zen Tsai, Hsin-Jung Li, Han-Chung Wu. (2020) Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science. 27, 1 (Invited review article) https://doi.org/10.1186/s12929-019-0592-z
- Ruei-Min Lu, Chiu CY, Liu IJ, Chang YL, Liu YJ, Wu HC. (2019) Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer. Cancer Science. 110, 3773-3787. https://doi.org/1111/cas.14208 PMID: 31578782
- Lo, W.L., Liang, C.H., Chen, L.C., Lee, S.Y., Lo, S.N., Chen, M.W., Ruei-Min Lu, Liu, I.J., Wu, H.C., Chang, C.H. (2020) Imaging, biodistribution and efficacy of radiolabeled SP90 peptide in BT-483 tumor bearing mice. Applied Radiation and Isotopes. 161, 109162. PMID: 332561130
- Wu, C. H., Liu, I. J., Ruei-Min Lu., Wu, H. C. (2016). Advancement and applications of peptide phage display technology in biomedical science. Journal of biomedical science. 23, 8. (Invited review article) PMID: 26786672
- Liao, M. Y., Lai, J. K., Kuo, M. Y. P., Ruei-Min Lu, Lin, C. W., Cheng, P. C., Liang, K. H., Wu, H. C. (2015). An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget 6, 16253-16270. PMID: 26317650
- De-Kuan Chang, Pi-Chun Li, Ruei-Min Lu, Wann-Neng Jane, Han-Chung Wu (2013) Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models. PLoS ONE 8, e83239. PMID: 24386166
- Ruei-Min Lu, Min-Shan Chen, De-Kuan Chang, Chien-Yu Chiu, Wei-Chuan Lin, Shin-Long Yan, Yi-Ping Wang, Yuan-Sung Kuo, Albert Lo, and Han-Chung Wu. (2013) Targeted drug delivery systems mediated by a novel peptide in breast cancer therapy and imaging. PLoS ONE 8, e66128. PMID: 23776619
- Cheng-Der Wu, Hung-Wen Chou, Yuan-Sung Kuo, Ruei-Min Lu, Yu-Chyi Hwang, Han-Chung Wu, Chin-Tarng Lin. (2012) Nucleolin antisense oligodeoxynucleotides induce apoptosis and may be used as a potential drug for nasopharyngeal carcinoma therapy. Oncology Reports 27, 94-100. PMID: 21956494
- Ruei-Min Lu, Yu-Ling Chang, Min-Shan Chen and Han-Chung Wu. (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32, 3265-3274. PMID: 21306768
- Tung-Ying Lu*, Ruei-Min Lu*, Mei-Ying Liao, John Yu, Chu-Hung Chung, Cheng-Fu Kao, and Han-Chung Wu. (2010) Epithelial Cell Adhesion Molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. The Journal of Biological Chemistry, 285, 8719-8732. (*Co-First Author) PMID: 20064925
- Hung-Hsi Chen, Jan-Growth Chang, Ruei-Min Lu, Tsui-Yi Peng, and Woan-Yuh Tarn. (2008) The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Molecular and Cellular Biology, 28, 6929-6938. PMID: 18794368
- Kai-Ti Lin*, Ruei-Min Lu*, and Woan-Yuh Tarn. (2004) The WW domain-containing proteins interact with the early spliceosome and participate in pre-mRNA splicing in vivo. Molecular and Cellular Biology, 24, 9176-9185. (*Co-First Author) PMID: 15456888
PATENTS
- Han-Chung Wu, Hsiao-Ling Chiang, Kang-Hao Liang, Ruei-Min Lu. The potently and broadly neutralizing human antibodies against SARS-CoV-2 from Alpha to Omicron. US provisional application, filing date May 2023.
- Han-Chung Wu, Ruei-Min Lu, Wan-Yu Chen, Hsiu-Ting Lin. Broadly Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 and Treatment Methods Using the Same. US provisional application No: 63/424,551, filing date Nov 11, 2022.
- Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Spain Patent, ES2882276T3
- Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Australia Patent, AU2016249991B2
- Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Singapore Patent, WO/2016/168159
- Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Canada Patent, CA2981883C
- Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. 抗血管新生及び標的がん療法のための抗VEGFR2ヒト抗体. Japan Patent, JP特許6542383B2
- Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody and methods of use thereof for detecting VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing cancer cell cytotoxicity. U.S. Patent
- Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-VEGFR2 human antibody for anti-angiogenic and targeted cancer therapy. Taiwan Patent, I621629
- Han-Chung Wu and Ruei-Min Lu. 抗c−met抗体及びその使用方法. Japan Patent, JP5955322B2
- Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. Taiwan Patent, I523867
- Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. European Union Patent, EP2611928
- Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. U.S. Patent, US9150655
- Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. China Patent, CN103415619B
- Han-Chung Wu, Tung-Ying Lu, Cheng-Fu Kao, John Yu and Ruei-Min Lu, and Mei-Ying Liao. Methods of inducing pluripotency. U.S. Patent, US8709806B2
HONORS And AWARDS
2023 Excellent Award for New Drug, NBRP Pitch Day
2022 Future Tech Award, National Science and Technology Council (NSTC)
2021 Newly Hired Academic Research Bonus Recipient, Academia Sinica, Taiwan
2015 Significant Research Achievements, 2015, Academia Sinica
2013 Poster Award, ICOB, Academia Sinica
2012 Significant Research Achievements, 2011, Academia Sinica
2011 The Third Prize of The 8th National Innovation Award-Student Research Contest
2011 Poster Presentation’s Award. The 19th Recent Advances in Cellular and Molecular Biology
2010 Bronze Medal Award. The 37th Military Medicine Symposium on Biomedical Research.
2010 Ph.D. student Research Poster Award. Graduate Institute of Life Sciences, National Defense Medical Center.
2003 Excellent Poster Award. The International Symposium on Genomics, Proteomics, Stem Cells and Biomedical Technology.
2003 Outstanding Poster Award. The 18th joint Annual Conference of Biomedical Sciences.
2000 Medical Laboratory Technologist License. Department of Health, Executive Yuan, Taiwan
1996-1998 Tzu-Chi Scholarship. Tzu-Chi Medical School
